Heparin-induced thrombocytopenia among patients of a comprehensive cancer center
Most clinical studies of heparin-induced thrombocytopenia have not included cancer patients who have high risk of thromboembolism, frequent exposure to heparin, and many potential causes of thrombocytopenia other than heparin-induced thrombocytopenia. To estimate the incidence and prevalence of hepa...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2014-07-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X14533945 |
| _version_ | 1818997185559134208 |
|---|---|
| author | Weixin Wu Kelly Merriman Amr Nabaah Nikhil Seval Vahid Afshar-Kharghan Sai-Ching J Yeung |
| author_facet | Weixin Wu Kelly Merriman Amr Nabaah Nikhil Seval Vahid Afshar-Kharghan Sai-Ching J Yeung |
| author_sort | Weixin Wu |
| collection | DOAJ |
| description | Most clinical studies of heparin-induced thrombocytopenia have not included cancer patients who have high risk of thromboembolism, frequent exposure to heparin, and many potential causes of thrombocytopenia other than heparin-induced thrombocytopenia. To estimate the incidence and prevalence of heparin-induced thrombocytopenia in cancer patients, we identified cases based on diagnostic codes, anti-heparin antibody testing, and clinical characteristics (4T score) at a comprehensive cancer center between 1 October 2008 and 31 December 2011. We estimated that the prevalence of heparin-induced thrombocytopenia to be 0.02% among all cancer patients and 0.24% among cancer patients exposed to heparin. The annual incidence of heparin-induced thrombocytopenia was 0.57 cases per 1000 cancer patients exposed to heparin. Of the 40 cancer patients with the International Classification of Diseases (Ninth Revision; ICD-9) code for heparin-induced thrombocytopenia, positive anti-heparin antibody, and 4T score ≥4, 5 (12.5%) died of related thromboembolic or hemorrhagic complications. In a multivariate logistic regression model, male gender was a significant ( p = 0.035) factor, and non-hematological malignancy was a significant ( p = 0.017) factor associated with anti-heparin antibody positivity. Future studies may further examine the risk factors associated with heparin-induced thrombocytopenia in larger cohorts. |
| first_indexed | 2024-12-20T21:41:37Z |
| format | Article |
| id | doaj.art-90bd13d6997a44519530b34db6da80d0 |
| institution | Directory Open Access Journal |
| issn | 2050-313X |
| language | English |
| last_indexed | 2024-12-20T21:41:37Z |
| publishDate | 2014-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj.art-90bd13d6997a44519530b34db6da80d02022-12-21T19:25:48ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2014-07-01210.1177/2050313X1453394510.1177_2050313X14533945Heparin-induced thrombocytopenia among patients of a comprehensive cancer centerWeixin Wu0Kelly Merriman1Amr Nabaah2Nikhil Seval3Vahid Afshar-Kharghan4Sai-Ching J Yeung5Zhongshan Hospital, Xiamen University, Xiamen, Fujian, People’s Republic of ChinaDepartment of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USAMost clinical studies of heparin-induced thrombocytopenia have not included cancer patients who have high risk of thromboembolism, frequent exposure to heparin, and many potential causes of thrombocytopenia other than heparin-induced thrombocytopenia. To estimate the incidence and prevalence of heparin-induced thrombocytopenia in cancer patients, we identified cases based on diagnostic codes, anti-heparin antibody testing, and clinical characteristics (4T score) at a comprehensive cancer center between 1 October 2008 and 31 December 2011. We estimated that the prevalence of heparin-induced thrombocytopenia to be 0.02% among all cancer patients and 0.24% among cancer patients exposed to heparin. The annual incidence of heparin-induced thrombocytopenia was 0.57 cases per 1000 cancer patients exposed to heparin. Of the 40 cancer patients with the International Classification of Diseases (Ninth Revision; ICD-9) code for heparin-induced thrombocytopenia, positive anti-heparin antibody, and 4T score ≥4, 5 (12.5%) died of related thromboembolic or hemorrhagic complications. In a multivariate logistic regression model, male gender was a significant ( p = 0.035) factor, and non-hematological malignancy was a significant ( p = 0.017) factor associated with anti-heparin antibody positivity. Future studies may further examine the risk factors associated with heparin-induced thrombocytopenia in larger cohorts.https://doi.org/10.1177/2050313X14533945 |
| spellingShingle | Weixin Wu Kelly Merriman Amr Nabaah Nikhil Seval Vahid Afshar-Kharghan Sai-Ching J Yeung Heparin-induced thrombocytopenia among patients of a comprehensive cancer center SAGE Open Medical Case Reports |
| title | Heparin-induced thrombocytopenia among patients of a comprehensive cancer center |
| title_full | Heparin-induced thrombocytopenia among patients of a comprehensive cancer center |
| title_fullStr | Heparin-induced thrombocytopenia among patients of a comprehensive cancer center |
| title_full_unstemmed | Heparin-induced thrombocytopenia among patients of a comprehensive cancer center |
| title_short | Heparin-induced thrombocytopenia among patients of a comprehensive cancer center |
| title_sort | heparin induced thrombocytopenia among patients of a comprehensive cancer center |
| url | https://doi.org/10.1177/2050313X14533945 |
| work_keys_str_mv | AT weixinwu heparininducedthrombocytopeniaamongpatientsofacomprehensivecancercenter AT kellymerriman heparininducedthrombocytopeniaamongpatientsofacomprehensivecancercenter AT amrnabaah heparininducedthrombocytopeniaamongpatientsofacomprehensivecancercenter AT nikhilseval heparininducedthrombocytopeniaamongpatientsofacomprehensivecancercenter AT vahidafsharkharghan heparininducedthrombocytopeniaamongpatientsofacomprehensivecancercenter AT saichingjyeung heparininducedthrombocytopeniaamongpatientsofacomprehensivecancercenter |